Search

In traditional service-oriented architecture(SOA),web service providers register their service descriptions in the registry for service consumers to discover and invoke services.Traditional SOA lacks dispute resolution mechanism,so that the trusted service invocation between service consumers and providers can not be guaranteed.Blockchain can be reasonably introduced into the dispute resolution mechanism due to its significant advantages in decentralization and tamper resistance.Therefore,this paper proposes a trusted SOA architecture based on blockchain,in which blockchain acts as evidence recorder and service registry agent. During a service trusted invocation,the service consumer first encrypts the parameters and sends them to the target service provider.Secondly,the service provider receives the encryption parameters and decrypts them.Then,the service provider completes the service execution and encrypts the output result.Finally,when the service provider sends the encryption result to the service consumer,it completes the trusted credential construction and uplink.Based on the above,when a service dispute occurs,it will trigger the adjudication of the smart contract.The execution of the contract relies on trusted vouchers to correctly handle service disputes.Experimental results show that,compared with the traditional invocation,the proposed method can correctly handle the service disputes between service providers and requesters on the premise of ensuring that the growth rate of trusted invocation time of most services is no more than 30%.

Abstract Background Fibronectin (FN) is known to be a large multifunction glycoprotein with binding sites for many substances, including N-terminal and C-terminal heparin-binding domains. We investigated the effects of highly purified rhFNHN29 and rhFNHC36 polypeptides originally cloned from the two heparin-binding domains on the adhesion and invasion of highly metastatic human hepatocellular carcinoma cells (MHCC97H) and analyzed the underlying mechanism involved. Methods The MHCC97H cells that adhered to FN in the presence of various concentrations of rhFNHN29 and rhFNHC36 polypeptides were stained with crystal violet and measured, and the effects of rhFNHN29 and rhFNHC36 on the invasion of the MHCC97H cells were then detected using the Matrigel invasion assay as well as a lung-metastasis mouse model. The expression level of integrins and focal adhesion kinase (FAK) phosphotyrosyl protein was examined by Western blot, and the activity of matrix metalloproteinases (MMPs) and activator protein 1 (AP-1) was analyzed by gelatin zymography and the electrophoretic mobility band-shift assay (EMSA), respectively. Results Both of the polypeptides rhFNHN29 and rhFNHC36 inhibited adhesion and invasion of MHCC97H cells; however, rhFNHC36 exhibited inhibition at a lower dose than rhFNHN29. These inhibitory effects were mediated by integrin αvβ3 and reversed by a protein tyrosine phosphatase inhibitor. Polypeptides rhFNHN29 and rhFNHC36 abrogated the tyrosine phosphorylation of focal adhesion kinase (p-FAK) and activation of activator protein 1 (AP-1), resulting in the decrease of integrin αv, β3 and β1 expression as well as the reduction of MMP-9 activity. Conclusions Polypeptides rhFNHN29 and rhFNHC36 could potentially be applicable to human liver cancer as anti-adhesive and anti-invasive agents.